🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 1 día
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 25/02/2010 | 39,93 | 40,19 | 39,18 | 40,14 | -0,55% | 2,53% | 1.107.800 |
| 24/02/2010 | 39,70 | 40,51 | 39,70 | 40,36 | +2,38% | 2,04% | 1.393.700 |
| 23/02/2010 | 39,61 | 40,16 | 39,04 | 39,42 | -1,25% | 2,83% | 1.637.500 |
| 22/02/2010 | 40,72 | 40,74 | 39,63 | 39,92 | -1,92% | 2,73% | 1.187.100 |
| 19/02/2010 | 40,23 | 40,72 | 40,23 | 40,70 | +1,12% | 1,22% | 982.800 |
| 18/02/2010 | 39,93 | 40,43 | 39,93 | 40,25 | +1,18% | 1,25% | 1.282.500 |
| 17/02/2010 | 38,80 | 39,98 | 38,74 | 39,78 | +2,84% | 3,20% | 1.522.300 |
| 16/02/2010 | 38,46 | 38,73 | 37,80 | 38,68 | +0,78% | 2,42% | 1.017.300 |
| 12/02/2010 | 37,76 | 38,39 | 37,76 | 38,38 | +0,73% | 1,67% | 1.311.300 |
| 11/02/2010 | 37,58 | 39,00 | 37,48 | 38,10 | +1,60% | 4,04% | 1.927.300 |
| 10/02/2010 | 37,77 | 37,90 | 37,11 | 37,50 | -1,06% | 2,09% | 693.800 |
| 09/02/2010 | 37,74 | 38,36 | 37,33 | 37,90 | +1,28% | 2,73% | 1.208.400 |
| 08/02/2010 | 37,00 | 37,60 | 37,00 | 37,42 | -0,51% | 1,62% | 1.685.900 |
| 05/02/2010 | 38,50 | 38,68 | 36,15 | 37,61 | -2,11% | 6,57% | 3.571.200 |
| 04/02/2010 | 39,78 | 39,84 | 38,27 | 38,42 | -4,50% | 3,95% | 2.192.500 |
| 03/02/2010 | 40,36 | 40,42 | 39,54 | 40,23 | -0,64% | 2,18% | 1.427.300 |
| 02/02/2010 | 39,25 | 40,50 | 38,93 | 40,49 | +2,92% | 4,00% | 2.024.000 |
| 01/02/2010 | 39,93 | 39,93 | 39,18 | 39,34 | +2,45% | 1,88% | 2.358.300 |
| 29/01/2010 | 38,75 | 39,17 | 38,36 | 38,40 | -0,65% | 2,09% | 1.322.600 |
| 28/01/2010 | 39,01 | 39,37 | 38,20 | 38,65 | -0,90% | 3,00% | 1.486.200 |
| 27/01/2010 | 38,81 | 39,34 | 38,63 | 39,00 | -0,05% | 1,83% | 1.908.200 |
| 26/01/2010 | 39,50 | 39,75 | 38,95 | 39,02 | -1,27% | 2,03% | 1.430.000 |
| 25/01/2010 | 40,23 | 40,34 | 39,41 | 39,52 | -1,54% | 2,31% | 1.107.800 |
| 22/01/2010 | 39,88 | 40,75 | 39,88 | 40,14 | +0,73% | 2,18% | 1.345.400 |
| 21/01/2010 | 40,96 | 40,96 | 39,54 | 39,85 | -2,18% | 3,47% | 1.876.600 |
| 20/01/2010 | 41,43 | 41,86 | 40,61 | 40,74 | -2,26% | 3,02% | 1.614.900 |
| 19/01/2010 | 40,33 | 41,78 | 40,33 | 41,68 | +3,66% | 3,60% | 2.199.700 |
| 15/01/2010 | 41,74 | 41,74 | 39,80 | 40,21 | -2,64% | 4,65% | 2.367.300 |
| 14/01/2010 | 42,48 | 42,69 | 41,11 | 41,30 | -3,32% | 3,72% | 1.892.600 |
| 13/01/2010 | 41,80 | 42,94 | 41,60 | 42,72 | +2,23% | 3,21% | 1.601.300 |